How Will Alcohol Research be Impacted by Future Reduction in Nicotine Content in Cigarettes?
How Will Alcohol Research be Impacted by Future Reduction in Nicotine Content in Cigarettes?
复制标题
未来香烟中尼古丁含量的减少将如何影响酒精研究？
DOI：
10.1111/acer.13869
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Pickworth,WallaceB
中科院分区：
文献类型：
--
作者：
Peters,EricaN;Herrmann,EvanS;Cohn,AmyM;Coleman-Cowger,VictoriaH;Smith,Carson;Koszowski,Bartosz;Pickworth,WallaceB
美国食品和药物管理局（FDA）正在采取前所未有的步骤来管制烟草产品，以改善公众健康。美国食品和药物管理局最近宣布，它打算制定产品标准，通过拟议规则制定的预先通知（ANPRM），将美国香烟中的尼古丁含量降低到最低或不会上瘾的水平（Gottlieb和Zeller， 2017）。由于吸烟与饮酒之间的紧密联系，有令人信服的理由让关注酒精的研究人员考虑未来强制性的市场范围内香烟中尼古丁含量的降低将如何对饮酒行为产生下游影响。本评论描述了ANPRM对酒精研究、治疗和政策的四个影响，其最终目标是帮助指导酒精领域处于最佳位置，以应对和利用ANPRM提供的机会来减少酒精相关疾病的流行。2009年的《家庭吸烟预防和烟草控制法》（TCA）赋予了FDA制定其认为适合保护公众健康的烟草产品标准的权力。2018年3月，FDA发布了一份ANPRM，征求公众意见，以考虑制定一项潜在的尼古丁产品标准，将尼古丁降至最低或非成瘾水平。目前，FDA尚未确定实际的尼古丁水平，并将继续评估新产品标准的潜在后果，然后再实施标准。
The United States (US) Food and Drug Administration (FDA) is taking unprecedented steps to regulate tobacco products in order to improve public health. The FDA recently announced its intention to set product standards to reduce the nicotine content in cigarettes available in the US to a minimally-or non-addictive level through an advance notice of proposed rulemaking (ANPRM)(Gottlieb and Zeller, 2017). Because of the strong connection of cigarette smoking to alcohol drinking, there is compelling reason for alcohol-focused researchers to consider how future mandated market-wide reductions of nicotine levels in cigarettes would have downstream impact on drinking behavior. This commentary describes four implications of the ANPRM on alcohol research, treatment, and policy, with the ultimate goal of helping to guide the alcohol field to be optimally positioned to react to and leverage the opportunity afforded by the ANPRM to reduce the alcohol-related disease epidemic.The Family Smoking Prevention and Tobacco Control Act (TCA) of 2009 gives FDA the authority to establish tobacco product standards that it determines to be appropriate for the protection of public health. In March 2018, the FDA issued an ANPRM seeking public comment for consideration to develop a potential nicotine product standard that would lower nicotine to a minimally-or non-addictive level. Currently, the FDA has not yet decided on the actual nicotine level and will continue to evaluate the potential ramifications of new product standards before putting a standard into place.